Last updated: August 18, 2026
Genentech, Inc. v. Sandoz Inc., No. 1:19-cv-00078, was a Delaware patent dispute involving Sandoz's proposed rituximab biosimilar and Genentech's patent rights relating to anti-CD20 antibody treatment. The case was part of the U.S. biosimilar patent pathway rather than a conventional Hatch-Waxman ANDA dispute. The Federal Circuit ultimately affirmed judgment favoring Sandoz, limiting the practical value of Genentech's asserted method-of-treatment patent against Sandoz's proposed product label. [1]
What product and patent were at issue in Genentech v. Sandoz?
The dispute concerned rituximab, the active antibody in Genentech's Rituxan product. Rituximab is used to treat certain B-cell malignancies, rheumatoid arthritis and other immune-mediated conditions.
Sandoz developed a rituximab biosimilar identified in the litigation as GP2013. Genentech alleged that Sandoz's proposed product and labeling would infringe U.S. Patent No. 9,340,614.
| Item |
Detail |
| Plaintiff |
Genentech, Inc. |
| Defendant |
Sandoz Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:19-cv-00078 |
| Filing year |
2019 |
| Reference product |
Rituxan, rituximab |
| Proposed biosimilar |
Sandoz GP2013 |
| Principal asserted patent |
U.S. Patent No. 9,340,614 |
| Federal Circuit citation |
Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022) |
| Core legal theory |
Patent infringement based on proposed biosimilar use and labeling |
| Ultimate outcome |
Judgment favoring Sandoz affirmed by the Federal Circuit |
The asserted patent was a method-of-treatment patent. It did not create a broad composition-of-matter monopoly over rituximab. The dispute therefore depended on whether Sandoz's proposed commercial labeling and intended use would encourage performance of the patented treatment method.
What did Genentech claim about Sandoz's biosimilar?
Genentech alleged infringement under the patent statute's pre-launch biosimilar litigation provisions. Its position was that Sandoz's proposed rituximab product, together with the proposed prescribing information, would lead physicians to practice Genentech's patented treatment method.
The dispute focused on the relationship among:
- The scope of the asserted method claims.
- The indications and dosing instructions in Sandoz's proposed label.
- Physician and patient use of the biosimilar.
- Induced infringement based on Sandoz's conduct and labeling.
The case did not turn on whether Sandoz's rituximab molecule was sufficiently similar to Rituxan. Biosimilar status and patent infringement are separate inquiries. A product can satisfy the FDA's biosimilarity standard while still infringing a valid method, formulation or manufacturing patent.
What was the key legal issue in the case?
The central issue was whether Sandoz's proposed label would actively encourage infringement of Genentech's patented treatment method.
A method-of-treatment patent generally requires proof that the accused product will be used in a manner covered by the patent claims. For a biosimilar manufacturer, the proposed label is critical. A label may include all approved indications, or it may omit patented uses through a partial or "skinny" label where FDA law permits.
The Federal Circuit examined whether the evidence showed that Sandoz's proposed labeling and product instructions would cause physicians to perform the claimed method. The court treated the label's text, rather than the mere availability of the product, as central to the inducement analysis. [1]
That distinction reduced Genentech's ability to rely on the ordinary clinical use of rituximab. Genentech needed to connect Sandoz's specific product instructions and commercial conduct to the claimed method.
How did the Federal Circuit decide Genentech v. Sandoz?
The Federal Circuit affirmed the judgment in Sandoz's favor. The appellate decision rejected Genentech's infringement theory based on the proposed label and the evidence in the record.
The decision is significant for biosimilar litigation because it reinforces several principles:
- A method patent is not automatically infringed because a biosimilar has the same active ingredient as the reference product.
- A manufacturer does not necessarily induce infringement merely by seeking approval for a biosimilar with overlapping clinical uses.
- The proposed label must be evaluated as a whole.
- Evidence of possible physician use cannot substitute for proof that the manufacturer encouraged the patented use.
- Genentech bears the burden of proving infringement under the applicable statutory and evidentiary standards.
The Federal Circuit's decision did not invalidate all Genentech patent rights relating to rituximab. It resolved the specific asserted patent and Sandoz's proposed product and labeling.
Was this an Orange Book or Paragraph IV case?
No. Rituxan is a biologic, so the dispute proceeded under the Biologics Price Competition and Innovation Act rather than the Hatch-Waxman ANDA framework.
| Issue |
Genentech v. Sandoz |
| FDA pathway |
BLA and biosimilar pathway under section 351(k) |
| Reference product |
Rituxan |
| Patent database |
Purple Book framework, not the Orange Book |
| Paragraph IV certification |
Not applicable |
| Patent dance |
Relevant BPCIA procedure |
| Statutory litigation trigger |
Submission and exchange of biosimilar information under the BPCIA |
| Generic-drug exclusivity analysis |
Not applicable in the conventional ANDA sense |
The case should not be characterized as a Paragraph IV challenge. Paragraph IV certifications apply to patents listed in the FDA's Orange Book for small-molecule drugs. Rituximab is regulated as a biologic, and biosimilar litigation uses different notice, information-exchange and patent-selection procedures.
What patent protection covered Rituxan and rituximab?
Genentech's rituximab patent estate included multiple categories of protection:
Composition and antibody patents
Early patents protected the anti-CD20 antibody and related biological materials. Many early rituximab patents had expiration dates before the 2019 filing of this case or were approaching the end of their enforceable terms.
Method-of-use patents
Genentech and related Roche entities obtained patents directed to treatment regimens, patient populations, combinations and dosing schedules. U.S. Patent No. 9,340,614 was the principal patent litigated in this action.
Method-of-use patents can retain commercial value after core molecule patents expire. Their value depends on claim breadth, the indications remaining on the reference-product label and whether a biosimilar manufacturer can omit the patented use.
Formulation patents
Rituximab formulation patents can cover concentration, stabilizers, surfactants, buffers and storage conditions. These patents may create a separate litigation path from method patents. The asserted patent in Genentech v. Sandoz was not a broad formulation patent dispute.
Manufacturing patents
Biologics also may be protected by cell-line, purification, glycosylation, analytical and process patents. A biosimilar applicant typically develops an independent manufacturing process, but process patents can create discovery and freedom-to-operate risks that do not appear from the product label alone.
When did Genentech's rituximab exclusivity expire?
Rituximab did not have a single exclusivity date. Its commercial protection was layered across regulatory exclusivity and multiple patents.
| Protection type |
Practical relevance |
| Biologic reference-product exclusivity |
Rituxan received the statutory reference-product exclusivity period applicable to biologics |
| Early molecule patents |
Core protection largely expired before or around the emergence of U.S. rituximab biosimilars |
| Method patents |
Some claims extended into the late 2020s or beyond, depending on patent and patent-term adjustment |
| Formulation patents |
Potentially created additional barriers, but required claim-specific analysis |
| Manufacturing patents |
Could remain relevant after launch and are independent of FDA reference-product exclusivity |
The asserted patent's expiration must be distinguished from Rituxan's overall loss of exclusivity. A single surviving patent does not preserve a complete product monopoly if competitors can launch without practicing the patent claims.
Did the case involve a settlement agreement?
The reported appellate decision resolved the case through judgment in Sandoz's favor. No publicly established settlement outcome is the basis for the Federal Circuit decision.
This distinction matters commercially. A settlement may impose a negotiated launch date or restrictions that are not apparent from a court judgment. Genentech v. Sandoz is better treated as an adjudicated biosimilar-label decision, not as a typical confidential launch-settlement case.
What was the litigation timeline?
| Date |
Event |
| 2019 |
Genentech filed suit against Sandoz in the District of Delaware |
| 2019-2021 |
The parties litigated patent scope, proposed labeling and infringement |
| 2021 |
The district court entered judgment favoring Sandoz |
| 2022 |
The Federal Circuit issued its decision in 55 F.4th 1368 |
| 2022 |
The appellate court affirmed the result for Sandoz |
The case was resolved before Genentech could obtain an injunction blocking Sandoz based on the asserted patent.
How strong was Genentech's patent estate after the decision?
Genentech's overall rituximab estate remained diversified, but the decision weakened one important enforcement route.
Strengths
- The estate contained different patent categories rather than relying only on one molecule patent.
- Method claims can remain enforceable after early composition patents expire.
- Biologic manufacturing processes are difficult to replicate and can create separate freedom-to-operate concerns.
- Clinical labeling and physician practice can create infringement exposure for biosimilar applicants.
Weaknesses
- The asserted method patent did not provide a product-wide bar to biosimilar entry.
- The Federal Circuit's label-focused analysis limits inducement theories based solely on overlapping indications.
- Narrow method claims are vulnerable to partial-label strategies.
- Rituximab biosimilars had multiple potential pathways to market as core exclusivity weakened.
The practical strength of the patent estate therefore depended on claim-by-claim analysis. Genentech retained potential leverage against other products or uses, but the Sandoz decision reduced the probability that the asserted patent alone could block a rituximab biosimilar launch.
Which companies challenged Rituxan exclusivity?
The competitive field included biosimilar developers and manufacturers pursuing rituximab products in the United States and international markets. Major competitors included Sandoz, Teva, Celltrion and Pfizer, among others.
Relevant U.S. rituximab biosimilars include:
| Product |
Sponsor |
Active ingredient |
| Truxima |
Celltrion/Teva |
Rituximab-abbs |
| Ruxience |
Pfizer |
Rituximab-pvvr |
| Riabni |
Amgen |
Rituximab-arrx |
Sandoz's litigation strategy illustrates a broader biosimilar model: challenge selected method claims while using labeling and indication management to reduce infringement exposure.
What generic or biosimilar launch risks remained after the decision?
The case reduced, but did not eliminate, launch risk for rituximab competitors.
Patent risk
Remaining risks could include unasserted method patents, formulation patents, manufacturing patents and patents covering specific dosing or combination regimens.
Regulatory risk
FDA approval depends on the biosimilar application, interchangeability requirements, manufacturing data and labeling. A favorable patent judgment does not guarantee regulatory approval.
Commercial risk
Rituximab markets contain hospital, oncology and specialty-pharmacy purchasing channels. Discounts, contracting and payer preferences can affect uptake more than the patent decision itself.
Indication risk
A biosimilar may launch with some indications while omitting others. That strategy can reduce patent exposure but may narrow the addressable market and create physician-education costs.
How does Genentech v. Sandoz compare with traditional generic litigation?
The case differs from a conventional generic-drug patent case in three important ways.
First, it involved a biologic, not a small-molecule drug. Second, there was no Paragraph IV certification or Orange Book patent listing. Third, infringement depended heavily on the proposed biosimilar's label and the manufacturer's conduct.
In an ANDA case, the applicant's filing itself commonly provides the statutory act of infringement and patent claims may cover the active ingredient, formulation or method. In a biosimilar case, patent disclosure and litigation are governed by the BPCIA, and the court may need to assess whether the proposed product and label would lead to infringement after launch.
Key Takeaways
- Genentech sued Sandoz in 2019 over a proposed rituximab biosimilar.
- The principal patent at issue was U.S. Patent No. 9,340,614.
- The dispute centered on method-of-treatment infringement and induced infringement through proposed labeling.
- The case proceeded under the BPCIA, not Hatch-Waxman.
- Paragraph IV and Orange Book concepts do not apply directly.
- The Federal Circuit affirmed judgment favoring Sandoz in 2022.
- The decision limited Genentech's ability to block biosimilar entry through the asserted method patent.
- Genentech's remaining rituximab patent estate could still include formulation, manufacturing and additional method claims.
- The decision did not invalidate every Genentech patent relating to Rituxan.
- Commercial launch risk remained claim-specific and dependent on labeling, manufacturing and regulatory status.
FAQs
What is the Federal Circuit citation for Genentech v. Sandoz?
The principal appellate citation is Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022).
Did Sandoz file a Paragraph IV certification against Rituxan?
No. Rituxan is a biologic, so Sandoz's challenge proceeded under the BPCIA biosimilar framework rather than the Hatch-Waxman Paragraph IV process.
Was U.S. Patent No. 9,340,614 a composition patent?
No. The litigation concerned method-of-treatment rights relating to anti-CD20 antibody therapy, not a broad composition-of-matter patent covering all rituximab.
Did Genentech obtain an injunction against Sandoz?
No. The Federal Circuit affirmed the judgment favoring Sandoz, so Genentech did not obtain an injunction based on the asserted patent in this case.
Does the decision clear all patent barriers to rituximab biosimilar entry?
No. It resolves the asserted patent and the specific Sandoz product and label. Other patents, manufacturing claims, formulation claims or method-of-use claims require separate analysis.
References
- Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022).
- Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7002, 124 Stat. 119, 804-821 (2010).
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- U.S. Food and Drug Administration. (2024). Rituxan (rituximab) prescribing information. Genentech, Inc.
- U.S. Patent No. 9,340,614. United States Patent and Trademark Office.
